NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
David S. Ettinger, Douglas E. Wood, Wallace Akerley et al. · Journal of the National Comprehensive Cancer Network · 2016
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.
Cited by 736 works. doi:10.6004/jnccn.2016.0031 Open-access PDF
Authors
- David S. Ettinger
- Douglas E. Wood
- Wallace Akerley
- Lyudmila A. Bazhenova
- Hossein Borghaei
- David Ross Camidge
- Richard T. Cheney
- Lucian R. Chirieac
- Thomas Anthony D’Amico
- Thomas J. Dilling
- M.C. Dobelbower
- Ramaswamy Govindan
- Mark W. Hennon
- Leora Horn
- Thierry Marie Jahan
- Ritsuko U Komaki
- Rudy P. Lackner
- Michael D. Lanuti
- Rogério Lilenbaum
- Jules Lin
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- SEER Cancer Statistics Review, 1975-2003
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Cancer statistics, 2016
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer